about
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesTriplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas.DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signalingInsights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeThe mitochondrial respiratory chain is essential for haematopoietic stem cell function.Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations.Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeMutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemiaConstitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemiaOntogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid LeukemiaGain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome
P50
Q24648438-8889E2B4-8037-4863-A988-E03C6ADF946FQ33691942-98A3098D-DD0D-4971-BF39-6AA7D6ABAAE5Q34530792-4BC1BB32-B4D6-45C2-9F72-0DCE353954DEQ35640834-3292D7AE-D9AA-44E0-80AA-BC280D41DCFFQ35780831-9B2BEDC0-9D4E-4F52-B518-E71B8D7C71F7Q36359558-98301E71-AEE9-48C8-959F-56A4DA05B478Q36730409-F596E709-32C9-4EA8-9001-C8D54C072B56Q37142140-FE038716-BB4B-462E-9BB9-DA46E831A618Q43280709-D2C2C94D-0B53-4EC9-95AF-984A95E10922Q47863498-6EA5DBB0-0770-4EF1-94C6-E252106859EDQ48579835-A2335B67-5157-462C-971A-6369B2B18C98Q51099410-26082B7A-E6CE-4CB5-921A-26CC4F952164Q79768063-E70C13CF-36EC-4B03-B213-242A9A72AAA7Q84354706-44B111A6-3524-43E2-8B66-58F706CD7358Q90710875-840DCCF9-A46A-42A7-BC77-77AD7641CC92Q90990008-0ADFCEBE-9A00-4AA9-BE7F-B37C8EAA779EQ95319226-350272A3-0CE0-4E3C-B0EE-365A97AAEBA8
P50
description
researcher ORCID ID = 0000-0002-9533-7778
@en
wetenschapper
@nl
name
Sébastien Malinge
@ast
Sébastien Malinge
@en
Sébastien Malinge
@nl
type
label
Sébastien Malinge
@ast
Sébastien Malinge
@en
Sébastien Malinge
@nl
prefLabel
Sébastien Malinge
@ast
Sébastien Malinge
@en
Sébastien Malinge
@nl
P31
P496
0000-0002-9533-7778